A5032096463- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Respiratory viral infections research
- Influenza Virus Research Studies
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Immunology Research
- SARS-CoV-2 detection and testing
- Diabetes and associated disorders
- Vaccine Coverage and Hesitancy
HKU-Pasteur Research Pole
2022-2024
University of Hong Kong
2022-2024
Few trials have compared homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines mRNA vaccines. The aim this study was to assess immune responses, safety, efficacy against SARS-CoV-2 infection following or third-dose either one dose CoronaVac (Sinovac Biotech; vaccine) BNT162b2 (Fosun Pharma-BioNTech; vaccine).
Whole virion inactivated vaccine CoronaVac (C) and Spike (S) mRNA BNT162b2 (B) vaccines differ greatly in their ability to elicit neutralizing antibodies but have somewhat comparable effectiveness protecting from severe COVID-19. We conducted further analyses for a randomized trial (Cobovax study, NCT05057169) of third dose homologous heterologous booster vaccination, i.e. four interventions CC-C, CC-B, BB-C BB-B. Here, we assess immunogenicity beyond function, including S non-S with Fc...
Abstract Vaccines that are broadly cross-protective against current and future SARS-CoV-2 variants of concern (VoC) or across the sarbecoviruses subgenus remain a priority for public health. Virus neutralization is best available correlate protection. To define magnitude breadth cross-neutralization in individuals with different exposure to infection vaccination, we here use multiplex surrogate assay based on virus spike receptor binding domains multiple VoC, as well related bat pangolin...
ABSTRACT Background There are few trials comparing homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines mRNA vaccines. Methods We conducted an open-label randomized trial in adults >=18 years age who received two vaccine (CoronaVac) or (BNT162b2) >=6 months earlier, randomised 1:1 ratio to receive a dose either vaccine. compared the reactogenicity, immunogenicity cell-mediated immune responses, assessed efficacy against infections during follow-up....
Abstract Cross-reactive antibodies with Fc receptor (FcR) effector functions may mitigate pandemic virus impact in the absence of neutralizing antibodies. In this exploratory study, we use serum from a randomized placebo-controlled trial seasonal trivalent influenza vaccination children (NCT00792051) conducted at onset 2009 H1N1 (pH1N1) and monitored for infection. We found that increases pH1N1 specific FcR functions. Furthermore, prospective baseline antibody profiles after vaccination,...
Abstract Vaccines that are broadly cross-protective against current and future SARS-CoV-2 variants of concern (VOC) or across the sarbecoviruses subgenus remain a priority for public health. Virus neutralization is best available correlate protection. We used sera from cohorts individuals vaccinated with two three doses RNA (BNT162b2) inactivated (Coronavac Sinopharm) vaccines without history previous SARS-CoV-1 (in 2003) infection, to define magnitude breath cross-neutralization in...